Skip to main content
Premium Trial:

Request an Annual Quote

Millennium to Acquire COR in $2B Stock Swap

NEW YORK, Dec. 6 - Millennium Pharmaceuticals said on Thursday it plans to acquire COR Therapeutics in a stock swap worth $2 billion.

 

Terms of the deal call for Millennium to trade 0.9873 of its shares for each COR share and to issue a total of 58 million shares to COR shareholders.

 

The deal will also plant four of COR's board members onto Millennium's board. Several members of COR's management team have also agreed to join Millennium management.

 

"By uniting the people and resources of Millennium and COR, we are executing on our plan to build the industry's leading biopharmaceutical company and deliver breakthrough personalized medicine that addresses some of the most significant therapeutic needs of patients," said Mark Levin, Millennium's CEO. He added the acquisition "provides commercial operating infrastructure, [and] leading-edge clinical and research programs" for Millennium.

 

Other details were not disclosed.

 

Last week, Millennium said it had begun Phase I clinical trials for its first molecule directed against a genomically derived target for metabolic disease.

 

The compound, called MLN4760, was synthesized by Millennium and was designed with the hope of providing a treatment for obesity. The company partnered with Abbott Park, Ill.-based Abbott Laboratories to develop the drug.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.